ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0240

Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features

Amir Razmjou1, Alexandra Klomhaus2, David Kellner3, Meika Fang4, Michael Weisman5 and John FitzGerald3, 1UCLA / Veterans Affairs, Los Angeles, CA, 2UCLA, Los Angeles, 3UCLA, Los Angeles, CA, 4VA Greater Los Angeles/UCLA, Los Angeles, CA, 5Cedars-Sinai Medical Center, LOS ANGELES, CA

Meeting: ACR Convergence 2025

Keywords: Behçet's Syndrome, Demographics, genetics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Behçet’s disease (BD) is a chronic systemic disease with heterogenous clinical presentations. The strongest genetic risk factor and diagnostic biomarker for BD is the class I major histocompatibility complex antigen HLA-B51. Although best studied in ‘Silk-Road’ populations, B51’s prevalence in BD varies considerably across different racial/ethnic groups (Capittini, et al. Dis Markers, 2021). The genetic risks in American populations with BD are limited. This study describes the associations between HLA-B alleles and demographics in a diverse BD population from a large urban academic medical center in Los Angeles County.

Methods: Inclusion criteria required that patients had HLA-B allele testing (by sequence-specific oligonucleotide-polymerase chain reaction typing) conducted in routine clinical care, and were identified as having BD with >2 ICD-9/10 codes for BD. A sensitivity analysis with a more restrictive cohort (>2 ICD-9/10 codes for BD, plus >1 rheumatology encounter, plus >1 DMARD prescription) was performed, and had similar demographic/genetic features. HLA-B alleles evaluated in the analysis included known relevant alleles (B51, B27), and the other 3 alleles of highest frequency.

Results: There were 144 identified BD patients, with B51 positivity in 33% (48 patients), versus a B51 prevalence of 11% among 2614 non-rheumatic controls (p< 0.0001). Amongst the BD patients, the alleles of highest frequency were B51 (49), B7 (31), B44 (28), and B35 (25) (Figure 1). Comparing B51(+) versus B51(-) BD patients, the groups were similar by age, gender, race/ethnicity and use of disease modifying agents (Table 1). However, there were higher percentages of B7(+) and B44(+) patients in the B51(-) group (Table 1). 35% of BD patients identified as white and compared to non-white BD patients had similar rates of B51(+), but a higher rate of B27(+) (16% vs 4%, p=0.01). White BD patients compared to white non-rheumatic controls had significantly higher B51(+) and B27(+). Non-white/Hispanic BD patients compared to non-white/Hispanic controls had significantly higher B51(+). The unadjusted odds ratios (OR) for BD (yes/no) demonstrated B51(+) 4.13 (95% CI 2.92, 5.85), female gender 3.5 (2.35, 5.30), and Hispanic ethnicity 0.48 (0.29, 0.77) (Figure 2). B51, gender, and Hispanic ethnicity remained significant in a multivariate model, and interaction terms were non-significant.

Conclusion: In a large diverse U.S. urban academic medical center, BD was significantly associated with B51(+) and was present in ~1/3 of BD patients. B51(+) did not differ significantly between race or ethnicity. White BD patients had significantly higher rates of B27(+) than non-rheumatic white controls, and non-white BD patients. This data shows that U.S. BD patients may have lower B51(+), and higher female prevalence than in Silk-Road BD populations, which may reflect different genetic/environmental risks for BD. Limitations include selection bias (patients had to have clinically indicated HLA-B allele testing), and misclassification bias utilizing ICD codes (though sensitivity analysis demonstrated similar baseline/genetic features).

Supporting image 1Values represent HLA-B allele count from total of 285 alleles (144 Behçet’s patients, 3 missing copies). Excluded the following HLA-B alleles representing < 3% prevalence, but still present at least once: HLA-B: 13, 37, 38, 39, 41, 42, 45, 46, 47, 48, 49, 50, 55, 56, 57, 58, 61, 63, 65, 67, 71, 72, 75, 77.

Supporting image 2Values represent n (%) for categorical variables, and mean (SD) for continuous variables.

Race, ethnicity, and gender are self-reported by the patient.

*p < 0.05, by Chi-Squared testing comparing B51(+) vs (-)

AAPI=Asian American/Pacific Islander, DMARD=disease modifying anti-rheumatic drug, csDMARD=conventional synthetic DMARD, bDMARD=biologic DMARD (RA=bDMARDs for RA, SpA=bDMARDs for spondyloarthritis, including IL17i, IL12/23i, IL23i), tsDMARD=targeted synthetic DMARD.

Supporting image 3Univariate logistic regressions for the outcome of Behçet’s Disease diagnosis.


Disclosures: A. Razmjou: None; A. Klomhaus: None; D. Kellner: None; M. Fang: None; M. Weisman: Spyre Therapeutics, 1, 2; J. FitzGerald: None.

To cite this abstract in AMA style:

Razmjou A, Klomhaus A, Kellner D, Fang M, Weisman M, FitzGerald J. Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/behcets-disease-in-a-diverse-urban-single-center-cohort-in-the-united-states-hla-b-alleles-and-clinical-features/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/behcets-disease-in-a-diverse-urban-single-center-cohort-in-the-united-states-hla-b-alleles-and-clinical-features/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology